
    
      This is a multi-centre, double-blind, placebo and active controlled, parallel 12 week
      treatment trial in men with signs and symptoms of benign prostatic hyperplasia, followed by a
      9 month open-label phase. The following procedures are used: physical exams,
      electrocardiograms, clinical laboratory tests, vital signs, the International Prostate
      Symptom Score, maximum urine flow rate, adverse events, concomitant medications, quality of
      life and compliance. 93 centres in 11 European countries (Finland, France, Germany, Italy,
      Netherlands, Poland, Romania, Russia, Spain, Ukraine, UK) will be involved
    
  